Showing: 1 - 2 of 2 RESULTS

Huge Questions for UK Govt After Spike in Virus Cases | Business News

By PAN PYLAS`, Associated Press

LONDON (AP) — The British government faced huge questions Monday over its coronavirus testing system after a tripling in the number of daily positive cases over the weekend that was blamed on a technical glitch.

Health Secretary Matt Hancock is due to make a statement to lawmakers later Monday after the opposition Labour Party asked the government to explain why the cases were not tabulated when they should have been.

The latest problems to afflict the U.K.’s test and trace program emerged over the weekend when public health officials revealed that a total of 15,841 virus cases weren’t tabulated from Sept. 25 to Oct. 2. The government said the “technical issue” was discovered Friday night and has now been resolved.

The unreported cases were added to the government’s daily new infections total over the weekend, boosting Saturday’s number to 12,872 cases and Sunday’s to 22,961. Before that, there had been signs that the number of new infections had been leveling off around the 7,000 a day mark, which Britain hit the preceding four days.

While all of those who tested positive were informed of the results, Public Health England said their contacts had not been traced.

For the test-and-trace program to work well, contacts should be notified within 48 hours. So authorities’ failure to inform people potentially exposed to the virus could lead to many more positive cases and the need for the government to impose further unwanted restrictions on everyday life.

Jonathan Ashworth, Labour’s spokesman on health issues, described the error as “shambolic’’ and said the public “will be understandably alarmed.’’

He said Hancock should tell lawmakers “what on Earth has happened, what impact it has had on our ability to contain this virus and what he plans to do to fix test and trace.”

The reporting error is just the latest problem with Britain’s test and trace system, which is seen as crucial to slowing the spread of COVID-19 and reducing the need for further limits on social interaction. Lawmakers from all parties have previously criticized Prime Minister Boris Johnson’s Conservative government for a shortage of testing capacity and delays in notifying people of their test results.

Paul Hunter, a professor in medicine at the University of East Anglia, said the news about the glitch is “very disappointing.”

“For the test, track and trace system to have a real impact on reducing transmission of COVID-19, it is essential that test results are communicated rapidly,” he said.

Like other countries in Europe, the U.K. has seen rising coronavirus infections over the past few weeks, which has prompted the government to announce a series of restrictions, both nationally and locally, to keep a lid on infections. They are largely centered on limiting the number of people allowed to gather together and putting a curfew on pubs in order to suppress the virus.

The U.K. has Europe’s highest virus-related death toll at more than 42,400. The government’s chief scientific advisers warned two weeks ago that the

Regenerative Medicine Market Huge Growth Opportunities and Trends to 2025

The MarketWatch News Department was not involved in the creation of this content.

Sep 29, 2020 (Market Insight Reports) —
The Regenerative Medicine Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2026. The Regenerative Medicine market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Regenerative Medicine Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Top Companies in the Global Regenerative Medicine Market
DePuy Synthes, Osiris Therapeutics, Medtronic plc (NYSE: MDT), Stryker Corporation (NYSE: SYK), Acelity, Zimmer Biomet Holdings, Inc. (NYSE: ZBH), UniQure, MiMedx Group, Cellular Dynamics International, Organogenesis, Vericel Corporation, Mesoblast, Guanhao Biotech, Vcanbio, Cytori, Golden Meditech, Bellicum Pharmaceuticals, Celgene, Gamida Cell, Stemcell Technologies, among others.

According to this study, over the next five years, the Regenerative Medicine market will register a 24.3% CAGR in terms of revenue, the global market size will reach $ 19360 million by 2025, from $ 8118.3 million in 2019.

Market Overview:
Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the “process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function”. It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body’s innate healing ability to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds, and ocular diseases.

Get a Sample PDF Copy of the Latest Research on Regenerative Medicine Market 2020 Before the purchase
https://www.marketinsightsreports.com/reports/01301807201/global-regenerative-medicine-market-growth-status-and-outlook-2020-2025/inquiry?Mode=46&Source=MW

According to the estimation of the World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, which has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of the Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.

The 21st Century Cures Act, approved in December 2016, created room for the establishment of the Regenerative Medicine Innovation Project (RMIP). NIH (National Institute of Health) is leading the RMIP in coordination with the FDA. The 21st Century Cures Act approved $30 million in federal awards over four years (2020-2020) for the RMIP, thus accelerating the arena by aiding clinical research on mature stem cells while endorsing the uppermost morals for scientific research and patient safety.

Market Insights:
Currently, some companies in the world can provide regenerative medicine services, mainly concentrating in the USA. The main market